[go: up one dir, main page]

MX2011008243A - Derivados y medicina de aminopirazina. - Google Patents

Derivados y medicina de aminopirazina.

Info

Publication number
MX2011008243A
MX2011008243A MX2011008243A MX2011008243A MX2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A
Authority
MX
Mexico
Prior art keywords
alkyl
medicine
amino
halogen atom
aminopyrazine derivative
Prior art date
Application number
MX2011008243A
Other languages
English (en)
Inventor
Tetsuo Asaki
Hidetaka Fujihara
Katsutoshi Hori
Haruna Naito
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2011008243A publication Critical patent/MX2011008243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto representado por la fórmula general [1] que satisface los siguientes (I) o (II), o una sal farmacéuticamente aceptable del compuesto. (I) X e CH o N; R' es un átomo de halógeno; y R2 es H, un átomo de halógeno, CN, [2], [3], [8], [9] , un O--alquilo, un -O- (anillo saturado) etc. [2]: -C(RC) (RD) (RE) {RC a RE cada uno es H, un alquilo, etc.} [3]: N(RF)(RG){RF y RG cada uno es H, OH, amino, un (hetero)arilo, etc.}[8]: -C(=O)RL {RL es un alquilo, OH, un alcoxi, amino, etc. } [9] : un fenilo (substituido); (II) X es >C-C(=O)RB {RB es un amino (substituido), un alcoxi, OH, etc.}; R' es un átomo de halógeno; R2 es H; R3 es H u OH; y R3 y R4 cada uno es H o un alquilo.
MX2011008243A 2009-02-06 2010-02-05 Derivados y medicina de aminopirazina. MX2011008243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009026470 2009-02-06
JP2009276133 2009-12-04
PCT/JP2010/051722 WO2010090290A1 (ja) 2009-02-06 2010-02-05 アミノピラジン誘導体及び医薬

Publications (1)

Publication Number Publication Date
MX2011008243A true MX2011008243A (es) 2011-08-17

Family

ID=42542181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008243A MX2011008243A (es) 2009-02-06 2010-02-05 Derivados y medicina de aminopirazina.

Country Status (19)

Country Link
US (2) US8673891B2 (es)
EP (1) EP2394999B1 (es)
JP (1) JP5263304B2 (es)
KR (1) KR101677778B1 (es)
CN (1) CN102307869B (es)
AU (1) AU2010211672B2 (es)
BR (1) BRPI1008661B8 (es)
CA (1) CA2751695C (es)
DK (1) DK2394999T3 (es)
ES (1) ES2453474T3 (es)
HR (1) HRP20140265T1 (es)
MX (1) MX2011008243A (es)
MY (1) MY155374A (es)
PL (1) PL2394999T3 (es)
PT (1) PT2394999E (es)
RU (1) RU2535217C2 (es)
SI (1) SI2394999T1 (es)
WO (1) WO2010090290A1 (es)
ZA (1) ZA201105623B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680055B2 (en) 2017-09-28 2023-06-20 Nippon Shinyaku Co., Ltd. Crystals

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394999B1 (en) * 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
SMT201700309T1 (it) 2009-06-29 2017-07-18 Agios Pharmaceuticals Inc Derivati di chinolin–8–solfonammide aventi un’attività anticancro
EP2491145B1 (en) 2009-10-21 2016-03-09 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JPWO2012005299A1 (ja) * 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
JPWO2012020786A1 (ja) * 2010-08-11 2013-10-28 日本新薬株式会社 医薬組成物
JP5668756B2 (ja) * 2010-08-11 2015-02-12 日本新薬株式会社 悪性リンパ腫治療剤
EP2702055A1 (en) * 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
KR101873543B1 (ko) 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012280725B2 (en) * 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
JP6026544B2 (ja) * 2011-09-27 2016-11-16 ノバルティス アーゲー 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類
EP3984997A1 (en) * 2012-01-06 2022-04-20 Les Laboratoires Servier SAS Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9187453B2 (en) 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
WO2015002230A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC CONNECTION
CA2917671A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MY185687A (en) 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JPWO2015016206A1 (ja) * 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
TN2016000121A1 (en) 2013-10-07 2017-10-06 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
JP2017214291A (ja) * 2014-10-09 2017-12-07 国立大学法人 宮崎大学 骨髄線維化の抑制剤
MD3307271T2 (ro) 2015-06-11 2024-01-31 Agios Pharmaceuticals Inc Metode de utilizare a activatorilor de piruvat kinază
HK1247607A1 (zh) 2015-06-11 2018-09-28 高等教育联邦系统-匹兹堡大学 P62-zz化學抑制劑
BR112018007671B1 (pt) 2015-10-15 2023-10-17 Les Laboratoires Servier Usos de um inibidor da idh1 e combinações
MA43000B1 (fr) 2015-10-15 2021-11-30 Celgene Corp Polythérapie pour le traitement de tumeurs malignes
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2023175932A1 (ja) * 2022-03-18 2023-09-21 日本新薬株式会社 高リスク骨髄線維症の治療剤
WO2025049402A1 (en) * 2023-08-28 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO2000071536A1 (en) 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
JP2003523942A (ja) * 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
US6495586B2 (en) * 2000-02-25 2002-12-17 The Regents Of The University Of California Scytonemin and methods of using thereof
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CN102627640A (zh) 2005-08-12 2012-08-08 默沙东公司 可用作p38激酶抑制剂的杂二环化合物
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN102131788B (zh) * 2008-04-07 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EP2394999B1 (en) * 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680055B2 (en) 2017-09-28 2023-06-20 Nippon Shinyaku Co., Ltd. Crystals

Also Published As

Publication number Publication date
JP5263304B2 (ja) 2013-08-14
BRPI1008661B8 (pt) 2021-05-25
US20130131082A1 (en) 2013-05-23
JPWO2010090290A1 (ja) 2012-08-09
WO2010090290A1 (ja) 2010-08-12
ES2453474T3 (es) 2014-04-07
HRP20140265T1 (hr) 2014-04-25
KR20110120932A (ko) 2011-11-04
MY155374A (en) 2015-10-15
AU2010211672A1 (en) 2011-08-25
CN102307869B (zh) 2014-10-22
CA2751695A1 (en) 2010-08-12
CA2751695C (en) 2017-11-28
SI2394999T1 (sl) 2014-05-30
ZA201105623B (en) 2012-07-25
AU2010211672B2 (en) 2016-08-04
CN102307869A (zh) 2012-01-04
US20110288065A1 (en) 2011-11-24
US8673891B2 (en) 2014-03-18
PL2394999T3 (pl) 2014-06-30
KR101677778B1 (ko) 2016-11-18
PT2394999E (pt) 2014-05-02
BRPI1008661A2 (pt) 2016-03-08
EP2394999B1 (en) 2014-01-29
RU2011136825A (ru) 2013-03-20
EP2394999A4 (en) 2012-10-10
US8586591B2 (en) 2013-11-19
EP2394999A1 (en) 2011-12-14
RU2535217C2 (ru) 2014-12-10
BRPI1008661B1 (pt) 2020-09-15
DK2394999T3 (da) 2014-05-05

Similar Documents

Publication Publication Date Title
MX2011008243A (es) Derivados y medicina de aminopirazina.
HRP20080429T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
EA200870336A1 (ru) Полициклические производные циннамида
PH12014501804A1 (en) Cycloalkane derivative
NZ627036A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
WO2009156861A8 (en) Substituted pyrimidone derivatives
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TW200745034A (en) New compounds
MY177250A (en) Novel nicotinamide derivative or salt thereof
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
NZ592284A (en) Pyrrolobenzodiazepines
MX2010008686A (es) Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo.
PH12012501773A1 (en) Arylethynyl derivatives
RS51545B (en) THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS
WO2008136444A1 (ja) 縮合複素環誘導体
TN2011000422A1 (en) Benzofuran derivatives
MY139887A (en) Tetrahydronaphthyridine derivatives and a process for preparing the same.
PH12014500831A1 (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
MX2022015330A (es) N-fenilaminocarbonil piridino-, pirimidino y benzo-tropanos como moduladores de gpr65.
MY183861A (en) Pyrazolopyrimidine derivative
PH12012501643A1 (en) Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
WO2009028387A1 (ja) プロテアーゼ阻害剤耐性を有する癌の治療薬
IN2013MN00506A (es)

Legal Events

Date Code Title Description
FG Grant or registration